Douglas Shepherd, MD
Physical Medicine & Rehabilitation · Layton, UTNPI 1659482289
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.
Across 72 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$204
- Averitas Pharma Inc.$139
- AbbVie$101
- Biodelivery Sciences International, Inc.$100
- Arbor Pharmaceuticals, Inc.$90
- Merz Pharmaceuticals, LLC$80
- plus $570 from 16 others
What the payments were for
- Food & beverage$1,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $204 |
| Averitas Pharma Inc. | 5 | $139 |
| AbbVie(2 entities) | 5 | $101 |
| Biodelivery Sciences International, Inc. | 7 | $100 |
| Arbor Pharmaceuticals, Inc. | 6 | $90 |
| Merz Pharmaceuticals, LLC | 2 | $80 |
| Pfizer | 4 | $79 |
| Collegium Pharmaceutical, Inc. | 5 | $68 |
| Azurity Pharmaceuticals, Inc. | 4 | $56 |
| Medtronic(2 entities) | 3 | $48 |
| Nevro Corp. | 2 | $47 |
| Boston Scientific | 2 | $42 |
| Scilex Pharmaceuticals Inc. | 3 | $41 |
| Abbott | 1 | $38 |
| AstraZeneca | 3 | $38 |
| Novo Nordisk | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| International Rehabilitative Sciences, Inc | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Shionogi Inc | 1 | $13 |
| Amgen | 1 | $11 |
How this compares
$1,284 in reported general payments places this provider in the 70th percentile of 117 physical medicine & rehabilitation providers in Utah.
See all physical medicine & rehabilitation providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tizanidine Hcl | 23 | $2,047 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $1,768 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $1,403 |
| Gabapentin | 35 | $446 |
| Carisoprodol | 34 | $347 |
| Tramadol Hcl | 32 | $303 |
| Diclofenac Sodium | 14 | $195 |
| Promethazine Hcl | 13 | $152 |
| Meloxicam | 13 | $68 |
| Diazepam | 16 | $10 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Layton
- Martin BertramLayton$5K
- Gregory RasmussenLayton$2K
- Brian MorganLayton$1K
- Dallin DemordauntLayton$516
- William BrandtLayton$369
- Scott AdelmanPark City$143K
- Judith GoochSlc$43K
- Colby BealSt George$25K
- Stephen AndersonBountiful$11K
- Timothy GrangeSalt Lake City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.